These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9137522)

  • 1. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
    Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
    J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
    Senan S; Rampling R; Graham MA; Wilson P; Robin H; Eckardt N; Lawson N; McDonald A; von Roemeling R; Workman P; Kaye SB
    Clin Cancer Res; 1997 Jan; 3(1):31-8. PubMed ID: 9815534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
    Robin H; Senan S; Workman P; Graham MA
    Cancer Chemother Pharmacol; 1995; 36(3):266-70. PubMed ID: 7781150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
    Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
    J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.
    Graham MA; Newell DR; Foster BJ; Calvert AH
    Cancer Chemother Pharmacol; 1989; 23(1):8-14. PubMed ID: 2909292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
    Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI; Workman P
    J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirapazamine-cisplatin: the synergy.
    Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation.
    Doherty N; Hancock SL; Kaye S; Coleman CN; Shulman L; Marquez C; Mariscal C; Rampling R; Senan S; Roemeling RV
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):379-82. PubMed ID: 8195037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.
    Fuse E; Kobayashi S; Inaba M; Suzuki H; Sugiyama Y
    J Natl Cancer Inst; 1994 Jul; 86(13):989-96. PubMed ID: 8024657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
    Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Fuchs T; Chowdhury G; Barnes CL; Gates KS
    J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
    Saeki T
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
    Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.